title: Sulphates of 3beta-hydroxy-5-ene steroids in women with epilepsy.
abstract: Epilepsy is associated with various reproductive disorders and some antiepileptic drugs also influence the steroid metabolism. There is only limited data concerning the role of steroid sulphates in human epilepsy. Moreover, the substitution treatment with therapeutic substances also improves cognitive functions in humans. Therefore, we evaluated the balance between free and Delta5 sulphated steroids in women with epilepsy on various antiepileptic drugs. The study included 28 patients (17.0-51.0 years), with generalized (n=16) or catamenial epilepsy (n=12) followed in the follicular (FP) and luteal (LP) phases of menstrual cycle. Fifteen patients were on monotherapy and 13 were on polytherapy with 2 or 3 drugs. RIA was used for the steroid analyses. Statistical evaluation was done by Mann-Whitney tests and multivariate regression with reduction of dimensionality (Orthogonal Projections to Latent Structures, O2PLS). The final O2PLS model found a single significant predictive component extracting the variability shared between carbamazepine therapy, age of the subjects, and steroid levels and correlating with the variables as follows pregnenolone sulphate (PregS)-FP: R= -0.844, p<0.01; DHEAS-FP: R= -0.923, p<0.01; PregS-LP: R= -0.876, p<0.01; DHEAS-LP: R= -0.902, p<0.01; carbamazepine therapy: R=0.441, p<0.01; age of the participants (R=0.584, p<0.01). Carbamazepine significantly decreased DHEAS in both FP (p=0.02) and LP (p=0.003) and PregS in LP (p=0.03) and tended to decrease the PregS levels in FP (p=0.10), while primidone decreased DHEAS in both FP and LP (both p=0.05) and did not significantly change the levels of PregS. In conclusion, carbamazepine and primidone therapies significantly suppressed the sulphated steroids in serum.
authors.affiliation: Institute of Endocrinology, Prague, Czech Republic and Charles University in Prague, First Faculty of Medicine and General University Hospital, Department of Obstetrics and Gynaecology, Prague, Czech Republic. mhill@endo.cz
authors.forename: M
authors.initials: M
authors.lastname: Hill
authors.forename: J
authors.initials: J
authors.lastname: Vrbíková
authors.forename: J
authors.initials: J
authors.lastname: Zárubová
authors.forename: H
authors.initials: H
authors.lastname: Vceláková
authors.forename: M
authors.initials: M
authors.lastname: Dusková
authors.forename: R
authors.initials: R
authors.lastname: Kancheva
authors.forename: J
authors.initials: J
authors.lastname: Kubátová
authors.forename: L
authors.initials: L
authors.lastname: Stárka
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood*; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005498:Follicular Phase; D006801:Humans; D008183:Luteal Phase; D008875:Middle Aged; D011284:Pregnenolone / Q000097:blood*; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; C018370:pregnenolone sulfate; D019314:Dehydroepiandrosterone Sulfate; D011284:Pregnenolone